CN110753692A - 作为h-pgds抑制剂的化学化合物 - Google Patents

作为h-pgds抑制剂的化学化合物 Download PDF

Info

Publication number
CN110753692A
CN110753692A CN201880039565.7A CN201880039565A CN110753692A CN 110753692 A CN110753692 A CN 110753692A CN 201880039565 A CN201880039565 A CN 201880039565A CN 110753692 A CN110753692 A CN 110753692A
Authority
CN
China
Prior art keywords
alkyl
naphthalene
carboxamide
substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880039565.7A
Other languages
English (en)
Chinese (zh)
Inventor
D.N.迪顿
B.G.希勒
M.A.扬曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN110753692A publication Critical patent/CN110753692A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880039565.7A 2017-06-13 2018-06-11 作为h-pgds抑制剂的化学化合物 Pending CN110753692A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762518779P 2017-06-13 2017-06-13
US62/518,779 2017-06-13
US201762522869P 2017-06-21 2017-06-21
US62/522,869 2017-06-21
PCT/IB2018/054206 WO2018229629A1 (en) 2017-06-13 2018-06-11 Chemical compounds as h-pgds inhibitors

Publications (1)

Publication Number Publication Date
CN110753692A true CN110753692A (zh) 2020-02-04

Family

ID=62948277

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039565.7A Pending CN110753692A (zh) 2017-06-13 2018-06-11 作为h-pgds抑制剂的化学化合物

Country Status (9)

Country Link
US (1) US11149035B2 (enExample)
EP (1) EP3638672A1 (enExample)
JP (1) JP2020523367A (enExample)
CN (1) CN110753692A (enExample)
BR (1) BR112019026452A2 (enExample)
CA (1) CA3066979A1 (enExample)
TW (1) TW201908311A (enExample)
UY (1) UY37764A (enExample)
WO (1) WO2018229629A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210139507A1 (en) * 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
BR112021008976A2 (pt) * 2018-11-08 2021-08-03 Glaxosmithkline Intellectual Property Development Limited compostos químicos
CN109651241B (zh) * 2018-12-27 2021-02-09 上海毕得医药科技股份有限公司 一种4-溴-6-氯烟醛的合成方法
JP7734129B2 (ja) 2020-06-19 2025-09-04 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
CN112430632B (zh) * 2020-11-18 2022-09-13 上海合全药物研发有限公司 2-((反式)-4-氨基环己烷基)异丙醇的制备方法
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
WO2009153720A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
AU2011208139A1 (en) * 2010-01-22 2012-08-02 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a PGDS inhibitory effect
EP2487175A1 (en) * 2009-10-06 2012-08-15 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical product containing aromatic heterocyclic compound
EP2661265A1 (en) * 2010-12-23 2013-11-13 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH1196397H1 (de) 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
EP2307378A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
MY154000A (en) 2008-09-22 2015-04-30 Cayman Chem Co Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CN102341385B (zh) 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制前列腺素d合酶的哌嗪化合物
JP2011042643A (ja) 2009-07-24 2011-03-03 Bayer Cropscience Ag 殺虫性カルボキサミド類
CA2776242C (en) 2009-10-08 2014-09-02 Sanofi Phenyloxadiazole derivatives as pgds inhibitors
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
BR112015001613B1 (pt) 2012-07-27 2021-02-23 Biogen Ma Inc compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica
ES2668694T3 (es) 2012-07-27 2018-05-21 Biogen Ma Inc. Derivados de ácido 1-[7-(cis-4-metil-ciclohexiloxi)-8-trifluorometil-naftalen-2-ilmetil]-piperidin-4-carboxílico como moduladores de autotaxina (ATX) para tratar inflamaciones y trastornos autoinmunitarios
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US9815797B2 (en) 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
EP3247692B1 (en) 2015-01-23 2022-09-07 GVK Biosciences Private Limited Inhibitors of trka kinase
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
JP6896701B2 (ja) * 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US20210139507A1 (en) * 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
WO2009153720A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
EP2487175A1 (en) * 2009-10-06 2012-08-15 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical product containing aromatic heterocyclic compound
AU2011208139A1 (en) * 2010-01-22 2012-08-02 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a PGDS inhibitory effect
EP2661265A1 (en) * 2010-12-23 2013-11-13 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators

Also Published As

Publication number Publication date
CA3066979A1 (en) 2018-12-20
TW201908311A (zh) 2019-03-01
BR112019026452A2 (pt) 2020-07-14
JP2020523367A (ja) 2020-08-06
EP3638672A1 (en) 2020-04-22
US11149035B2 (en) 2021-10-19
WO2018229629A1 (en) 2018-12-20
US20200123152A1 (en) 2020-04-23
UY37764A (es) 2019-01-02

Similar Documents

Publication Publication Date Title
CN112752756B (zh) 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
CN112135824B (zh) 作为免疫调节剂的杂环化合物
CN109923114B (zh) 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
CN104470919B (zh) 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑
TWI498325B (zh) ３－取代吡唑及其用途
WO2023109883A1 (zh) 一类芳杂环取代的化合物及其制备方法和用途
TW201908311A (zh) 化合物
CN108430992A (zh) 作为h-pgds抑制剂的喹啉-3-甲酰胺
CN109195969B (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN107820494B (zh) 核受体调节剂
CN114728975A (zh) 唑稠合的哒嗪-3(2h)-酮衍生物
CN103298468A (zh) 稠环杂环衍生物
CN110582493A (zh) 作为免疫调节剂的苯并噁唑衍生物
JP2025526423A (ja) 新規化合物
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
CN106029076A (zh) 作为bet溴域抑制剂的苯并哌嗪组合物
TW201629067A (zh) 稠合五環咪唑衍生物
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN112088157A (zh) 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
CN115702024A (zh) 用作il-17调节剂的二氟环己基衍生物
CN101981031A (zh) 具有促肾上腺皮质激素释放因子拮抗活性的三环化合物和含有它们的药物组合物
CN107207521A (zh) 作为沉默调节蛋白调节剂的取代的桥连脲类似物
CN111479814A (zh) 作为h-pgds抑制剂的稠合的吡啶
CN109219608B (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200204

WD01 Invention patent application deemed withdrawn after publication